Sophie Gravia and Christine McGuinness talk relationships in new BBC podcast
Christine said: 'I am so excited to be hosting this podcast with Sophie. It'll be real, raw and, most importantly, judgement-free. We'll be chatting all things love, relationships, and everything in between.'
Award winning writer Sophie Gravia, known for her hilarious, sexy and brutally honest novels, and TV personality, model and fellow best-selling author, Christine McGuinness, are coming together to host a brand-new podcast, Situationships with Sophie and Christine, commissioned by BBC Scotland for BBC Sounds.
Each week, audiences will be taken on a rollercoaster ride of funny, bizarre and downright weird stories of when relationships take an unexpected turn. The podcast will see the duo delve into listeners' dating dilemmas, relationship revelations and situationship struggles.
As well as offering judgement-free advice, Sophie and Christine will give a glimpse into their own lives and situationships as they juggle the pressures of dating, parenting and their careers.
The Bolton News previously reported that Christine McGuiness quit Celebs Go Dating after revealing that she is "not ready" to date in the public eye.
The media personality, who was previously married to Bolton TV presenter Paddy McGuinness, announced that she originally "joined Celebs Go Dating with great intentions" but soon realised that dating on such a public platform is "too soon".
Situationships with Sophie and Christine will be fully visualised and available on BBC Sounds, BBC Scotland and BBC iPlayer from 19 June.
READ MORE:
Heather Kane Darling, Commissioning Editor BBC Scotland, says: 'We are delighted to be bringing this brand-new podcast to audiences across the UK. Sophie and Christine are the perfect duo to take audiences through the highs and lows of relationships and dating. Everyone's welcome in Club Situationships!'
Word-of-mouth sensation Sophie has never shied away from the messy, hilarious realities of modern relationships. Raised just outside Glasgow, Sophie began sharing her unfiltered dating adventures in her twenties while working as an NHS nurse. Her blog, Sex in the Glasgow City, quickly became a cult hit, striking a chord with readers across the UK.
Riding the wave of her blog's success, Sophie's debut novel A Glasgow Kiss soared straight to number one in the erotic fiction charts. Now, five years on and over quarter of a million book sales later, she's gearing up to release her fifth novel, The Dicktionary Club.
Juggling her writing career with life as a single mum, a full-time NHS nurse, and the occasional situationship of her own, Sophie has become the ultimate go-to confidante for fans and friends alike. Honest, relatable, and always hilarious, she continues to turn life's dating disasters into literary gold.
Sophie says: 'Fronting this podcast alongside Christine is an absolute dream. Just like a girls' night in, no topic is off limits, and we will be diving headfirst into the comedy, chaos and sometimes downright cringe of dating. I cannot wait to chat through our own outrageous stories together and of course hear the dating dilemmas sent in by listeners.'
Blackpool-born Christine McGuiness wears many hats as a TV personality, model and author. Recently fronting her own BBC One documentary Unmasking My Autism, Christine has been raw and honest about her own experiences, passionately advocating for positive representation of autistic women in the media.
While navigating her busy career, parenting and dating life, Christine will give an exclusive insight into her own personal life and offer her own advice to listeners.
Listen to Situationships with Sophie and Christine on BBC Sounds from Thursday 19 June
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Treatment for advanced womb cancer ‘major step forward'
Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for widespread NHS use. Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
Yahoo
5 hours ago
- Yahoo
RSV symptoms as 'serious virus' coming to UK after Australia surge
NHS experts have urged people who are eligible for a vaccine against respiratory syncytial virus (RSV) to take it up after cases surged in Australia. Australia saw a record number of RSV cases last year, and NHS officials have suggested that the Australian winter often provides a good indication of how viruses will spread in England. Since the start of 2025, the virus has been progressively spreading, with nearly half of reported cases occurring in children under five years old. Kate Brintworth, chief midwifery officer for NHS England, said: "Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating." READ MORE: Walker spots giant 'alien' jellyfish washed up on beach READ MORE: Warning over serious virus affecting newborns after surge in cases Dr Andy Whittamore, GP and clinical lead at Asthma + Lung UK, who has pointed out the key symptoms to watch out for and shared some strategies to help protect yourself and your family. What is RSV? He said: "Respiratory syncytial virus is a virus that causes symptoms very similar to the common cold, most of us get it at some point and don't even know that we've had it." According to Asthma + Lung UK, up to 9 in 10 children will contract RSV before they turn two years old and around 175,000 people over the age of 65 visit their GP about RSV each year. How does it spread? Dr Whittamore said: "Like most respiratory viruses, RSV spreads by people coughing and sneezing droplets from their own respiratory tract and it is spread to other people that way, It is often spread and caught in the air, by contact or if it ends up on surfaces." While RSV can circulate all year round, it typically peaks during the colder months. He said: "We see a major peak in cases in the NHS between October and February, particularly in December/January time." What are the most common symptoms? "As a GP, I see a lot of people with respiratory viruses and you can't really tell whether it's flu, Covid, RSV or the common cold," Dr Whittamore says. "Common symptoms are a runny nose, blocked nose, sneezing, coughing, feeling tired etc. People might also have a fever with it and if it's affecting their respiratory system itself, they might experience breathless or wheezing as well." A high temperature is also another key sign to look out for, according to the NHS website. Dr Whittamore said: "For most people, these symptoms tend to last no more than a week to 10 days." Can it lead to any serious complications? RSV can lead to some serious complications such as pneumonia or bronchiolitis for high-risk groups such as babies, young children and older people. Dr Whittamore said: "What we see with RSV, especially in younger children under the age of two, is that it can cause bronchiolitis, which causes quite dramatic breathing effects which can quite often put people in hospital. "We are also seeing that RSV is having a big impact on people over 75. We know that in that age group, the virus is more likely to cause them problems with their breathing and could go on and cause pneumonia and is likely to increase their chances of going to hospital." The NHS website also states that individuals with weakened immune systems, or long-term lung or heart conditions, and those who smoke tobacco are also at risk. A more serious infection (such as pneumonia or bronchiolitis) may cause a cough that gets worse, shortness of breath, noisy breathing (wheezing), faster breathing or long gaps between breaths, difficulty feeding in babies or loss of appetite, and confusion in older adults, according to the NHS website. How is it treated? RSV often improves on its own in one or two weeks, so you can usually manage it at home. Dr Whittamore said: "One important thing to do is to keep well hydrated, people with RSV should be pushing their fluids, resting more, taking paracetamol and can usually monitor themselves. However, if you are worried about yourself or your child, then seek advice from your GP or call 111." Can it be prevented? There are some measures you can take to reduce your chances of contracting RSV or spreading it to anyone else. Dr Whittamore said: "Make sure that when you are blowing your nose or sneezing that you use a tissue and throw it away, also, remember to wash your hands and clean surfaces regularly." The GP emphasises that the most crucial way to prevent people from falling ill with RSV is to ensure you receive the RSV vaccination if you are eligible for it. The RSV jab is recommended if you're expecting (from 28 weeks of pregnancy) – to help safeguard your baby for the first few months after they're born – or if you're aged between 75 and 79. Fresh research from the UK Health Security Agency (UKHSA) has revealed the RSV vaccine is around 82% effective in preventing older people being hospitalised with an RSV infection. "Most GP practices are contacting people and inviting them in, but if somebody thinks they're eligible and haven't been contacted they should contact their GP surgery and see if they can get it booked in," recommends Dr Whittamore.
Yahoo
7 hours ago
- Yahoo
Thousands of patients miss out on weight loss jab due to NHS ‘postcode lottery'
Thousands of obese patients are missing out on a key weight loss jab due to a 'postcode lottery' of provision in the NHS, according to a report. Mounjaro, dubbed the 'King Kong' of weight loss medicine, was supposed to be available through GP surgeries from 23 June under an agreement between NHS England and NICE. But just eight out of 42 NHS Integrated Care Boards (ICBs) in England were able to provide treatment to patients, according to Sky News, who obtained the data using a Freedom of Information request. Many other ICBs were reportedly unable to confirm when treatment would be available. Dr Jonathan Hazlehurst, an endocrinologist and obesity physician at University Hospitals Birmingham, said patients were 'set up for failure' and have been treated unfairly. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair. That's what the current system is doing,' he told the broadcaster. NICE said in December that the NHS should offer Mounjaro to patients with a BMI of over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazlehurst claims NHS England has only provided funding for just over 22,000 patients. The Independent has approached NHS England for comment. A spokesperson told Sky News that NHS England had "fully supported the rollout" of Mounjaro. "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services,' they said. It comes after NICE warned many individuals might regain weight if not adequately supported after ceasing treatment. It stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. The new 'quality standard' from NICE says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made.'
